Company intelligence / Profile preview

NeuroSnap

Wilmington, Delaware, United States

Ownership: Private
Development stage: Other

Overview

NeuroSnap delivers over 45 AI-powered bioinformatics tools including proprietary protein/enzyme design (NeuroFold), structure prediction, and molecular screening, supporting rapid and reliable in silico modeling for drug discovery and synthetic biology. Their tools are widely adopted for speeding up protein engineering, drug discovery, and omics analysis across academic/industrial research institutes. No clinical-stage drug assets have been announced.

Modalities: Small moleculePeptidesProteinMonoclonal antibodyAntibodyEnzyme
Industry: Drug Discovery Services

Beyond the preview

Go deeper on NeuroSnap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSnap.

Explore the full profile